# VIALE-T (NCT04161885)

> A Study Evaluating Safety and Efficacy of Venetoclax in Combination With Azacitidine Versus Standard of Care After Allogeneic Stem Cell Transplantation (SCT) in Participants With Acute Myeloid Leukemia (AML)

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04161885
- Phase: PHASE3
- Status: TERMINATED
- Sponsor: AbbVie
- Conditions: Acute Myeloid Leukemia (AML); Cancer
- Interventions: Venetoclax; Azacitidine; Best Supportive Care (BSC)
- Enrollment: 465
- Primary outcome: Number of Participants With Dose-Limiting Toxicities (DLTs) Following Administration of Venetoclax and Azacitidine (Part 1)
- Primary outcome: Overall Survival (OS) (Part 2)

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- X threads: 6
- Podcasts: 2
- Bluesky threads: 2

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=viale-t-nct04161885

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT04161885", "email": "<work email>"}; the inbox owner confirms by the emailed link.